Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.
Human immunodeficiency type 1 isolates from 18 initially symptom-free men who were treated with zidovudine for 2 years were investigated for drug sensitivity. At the start all the men had persistent core antigenaemia; the acquired immunodeficiency syndrome developed in 6 during the study. The polymerase chain reaction was used to detect mutations at residue 215 of reverse transcriptase, a mutation associated with reduced drug sensitivity. After 2 years 16/18 isolates were mutant. However, after about 6 months of treatment the mutation was detected in only 7 isolates, 4 from individuals who subsequently had AIDS. Limited direct virus sensitivity data correlated with the genetic data. The rate of appearance of the 215 mutation seemed to correlate with CD4 counts and viral virulence.
Boucher
C A
CA
Human Retrovirus Laboratory, University of Amsterdam, Netherlands.
Tersmette
M
M
Lange
J M
JM
Kellam
P
P
de Goede
R E
RE
Mulder
J W
JW
Darby
G
G
Goudsmit
J
J
Larder
B A
BA
D015704:CD4 Antigens / Q000302:isolation & purification; D004252:DNA Mutational Analysis; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000187:drug effects; D015497:HIV-1 / Q000187:drug effects*; D006716:Homosexuality; D006801:Humans; D008297:Male; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000627:therapeutic use*
D015704:CD4 Antigens; D004279:DNA, Viral; D015215:Zidovudine